News | Radial Access | December 30, 2019

Merit Medical Announces its EVOlution in Radial Hemostasis in Europe

The product has FDA clearance in the U.S. and CE Mark approval in the EU for use in diagnostic cardiac catheterisation procedures and percutaneous coronary interventions


December 30, 2019 — Merit Medical Systems Inc., a leading manufacturer of proprietary devices used primarily in cardiology, radiology, oncology and endoscopy, announces the commercial launch of the PreludeSYNC EVO radial compression device in European, Middle Eastern and African markets.

The product has FDA clearance in the U.S. and CE Mark approval in the EU for use in diagnostic cardiac catheterisation procedures and percutaneous coronary interventions.

Merit’s PreludeSYNC EVO is a sterile, single-use, disposable device used to assist in gaining haemostasis of the arterial percutaneous access site following catheterisation procedures.

“PreludeSYNC EVO adds to our extensive line of radial compression devices that support PCI from start to finish. It was developed to meet the evolving clinical and health economic needs of physicians, administrators and cath lab teams around the globe. Our intent with PreludeSYNC EVO, the latest innovation in our premium cardiology product portfolio, is to provide physicians with even more procedural clarity and uniformity and their patients with safety and comfort,” said Fred P. Lampropoulos, Merit Medical’s Founder, Chairman, and Chief Executive Officer

The need for clarity and uniformity is fulfilled by PreludeSYNC EVO’s large clear window area with unobstructed site visibility. It is also optimised for diffuse and uniform balloon pressure. The safety features include a specialised connection and Slip-n-Lock cap which secures the syringe during inflation and deflation. A soft comfortable band, which is easy to secure, adjust and clean, is available in 24 and 29 cm sizes.

The PreludeSYNC EVO is immediately available in the EU, with registration coming in Middle East and Africa. 

For more information: www.merit.com


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now